Few truly innovative drugs for central nervous system (CNS) disorders have been approved in recent years, suggesting that there is a need for strategies to improve the productivity of research and development in this field. The authors describe approaches that are being taken to discover CNS drugs, discuss their relative merits and consider how risk can be balanced and attrition reduced.
- Menelas N. Pangalos
- Lee E. Schechter
- Orest Hurko